4.7 Review

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology

Journal

LANCET ONCOLOGY
Volume 16, Issue 7, Pages E322-E332

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(15)00076-5

Keywords

-

Categories

Funding

  1. Varian
  2. BrainLAB AG
  3. GlaxoSmithKline
  4. Roche
  5. Boehringer Ingelheim
  6. Bristol-Myers Squibb
  7. Medac
  8. Merck Serono
  9. Isarna
  10. Novocure
  11. Bayer
  12. Piqur
  13. Celldex
  14. Magforce

Ask authors/readers for more resources

The management of primary CNS lymphoma is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the very few controlled studies available. In 2013, the European Association of Neuro-Oncology created a multidisciplinary task force to establish evidence-based guidelines for immunocompetent adults with primary CNS lymphoma. In this Review, we present these guidelines, which provide consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma. Specifically, we address aspects of care related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients. The guidelines should aid clinicians in their daily practice and decision making, and serve as a basis for future investigations in neuro-oncology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available